German cancer specialists have made significant progress in the development of a vaccine against renal cell carcinoma, with first test results looking promising, it was reported on Monday. The first study of the vaccine was conducted on 19 patients with renal cell carcinoma so advanced that other forms of therapy were no longer effective, with 10 of the patients completing the full series of vaccinations. "Seven of these patients are still alive and have had their disease stabilized for up to 65 weeks," Ingo Schmidt-Wolf of the Center for Integrated Oncology in Bonn, Germany, told the 2012 European Society for Medical Oncology in Vienna. He added that quality of life for the patients improved during the course of the treatment, and that side-effects were relatively minor. For two of the patients, the disease came to a still-stand within 12 weeks, and upon continued administration of the vaccine experienced remission and eventually stabilization. Phase II of the clinical study is currently planned and will be aimed at patients for whom a first or second treatment strategy has lost effectiveness and where the vaccine is a further option.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor